A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Avelumab (Primary) ; Entinostat (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ENCORE 603
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 10 Aug 2017 According to a Syndax Pharmaceuticals media release, the company recently began enrolling patients into the phase 2 portion and is expected to complete enrollment in the first half of 2018.
    • 08 May 2017 According to a Syndax Pharmaceuticals media release, company expects to begin the Phase 2 portion of the trial in the third quarter of 2017.
    • 02 Mar 2017 According to a Syndax Pharmaceuticals media release, company initiated enrollment of patients in the Phase 1b portion of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top